AMA
Douxfils J, Foidart J, Gaspard U, et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815.
APA
Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., & Jost, M. et al. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), 117-119. https://doi.org/10.5114/pm.2023.128815
Chicago
Douxfils, Jonathan, Jean-Michel Foidart, Ulysse Gaspard, Guillaume Chatel, Mélanie Taziaux, Maud Jost, and Céline Gérard et al. 2023. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy". Menopause Review/Przegląd Menopauzalny 22 (2): 117-119. doi:10.5114/pm.2023.128815.
Harvard
Douxfils, J., Foidart, J., Gaspard, U., Chatel, G., Taziaux, M., Jost, M., Gérard, C., and Morimont, L. (2023). Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny, 22(2), pp.117-119. https://doi.org/10.5114/pm.2023.128815
MLA
Douxfils, Jonathan et al. "Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy." Menopause Review/Przegląd Menopauzalny, vol. 22, no. 2, 2023, pp. 117-119. doi:10.5114/pm.2023.128815.
Vancouver
Douxfils J, Foidart J, Gaspard U, Chatel G, Taziaux M, Jost M et al. Response to paper by Binkowska et al. Risk of venous thromboembolism during the use of oral estrogen-progestogen
hormone therapies in light of most recent research findings. Commentary: Oestradiol is not the holy grail in the quest for
the ideal oestrogen therapy. Menopause Review/Przegląd Menopauzalny. 2023;22(2):117-119. doi:10.5114/pm.2023.128815.
